ZA201506050B - Vortioxetine manufacturing process - Google Patents

Vortioxetine manufacturing process

Info

Publication number
ZA201506050B
ZA201506050B ZA2015/06050A ZA201506050A ZA201506050B ZA 201506050 B ZA201506050 B ZA 201506050B ZA 2015/06050 A ZA2015/06050 A ZA 2015/06050A ZA 201506050 A ZA201506050 A ZA 201506050A ZA 201506050 B ZA201506050 B ZA 201506050B
Authority
ZA
South Africa
Prior art keywords
vortioxetine
manufacturing process
manufacturing
vortioxetine manufacturing
Prior art date
Application number
ZA2015/06050A
Other languages
English (en)
Inventor
Lasse Christensen Kim
Ruhland Thomas
Original Assignee
H Lundbeck As A Danish Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As A Danish Company filed Critical H Lundbeck As A Danish Company
Publication of ZA201506050B publication Critical patent/ZA201506050B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
ZA2015/06050A 2013-02-22 2015-08-20 Vortioxetine manufacturing process ZA201506050B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300104 2013-02-22
PCT/EP2014/053313 WO2014128207A1 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Publications (1)

Publication Number Publication Date
ZA201506050B true ZA201506050B (en) 2017-08-30

Family

ID=59215387

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/06050A ZA201506050B (en) 2013-02-22 2015-08-20 Vortioxetine manufacturing process

Country Status (37)

Country Link
US (1) US9353073B2 (enExample)
EP (1) EP2958903B1 (enExample)
JP (1) JP6464098B2 (enExample)
KR (1) KR102230628B1 (enExample)
CN (1) CN104995181B (enExample)
AP (1) AP2015008640A0 (enExample)
AU (1) AU2014220735B2 (enExample)
BR (1) BR112015019268B1 (enExample)
CA (1) CA2901821A1 (enExample)
CL (1) CL2015002309A1 (enExample)
CR (1) CR20150423A (enExample)
CY (1) CY1118883T1 (enExample)
DK (1) DK2958903T3 (enExample)
DO (1) DOP2015000187A (enExample)
EA (1) EA027756B1 (enExample)
ES (1) ES2625380T3 (enExample)
GE (1) GEP201706749B (enExample)
HR (1) HRP20170607T1 (enExample)
IL (1) IL240501B (enExample)
LT (1) LT2958903T (enExample)
MA (1) MA38338B1 (enExample)
ME (1) ME02671B (enExample)
MX (1) MX362355B (enExample)
MY (1) MY172337A (enExample)
PE (1) PE20151589A1 (enExample)
PH (1) PH12015501807B1 (enExample)
PL (1) PL2958903T3 (enExample)
PT (1) PT2958903T (enExample)
RS (1) RS55932B1 (enExample)
RU (1) RU2652265C2 (enExample)
SG (1) SG11201506651SA (enExample)
SI (1) SI2958903T1 (enExample)
SM (1) SMT201700238T1 (enExample)
TN (1) TN2015000335A1 (enExample)
UA (1) UA116236C2 (enExample)
WO (1) WO2014128207A1 (enExample)
ZA (1) ZA201506050B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340997B (es) 2010-08-18 2016-08-03 Samumed Llc Dicetonas e hidroxicetonas como activadores de la trayectoria de señalizacion de catenina.
SG11201506592SA (en) 2013-02-22 2015-09-29 Samumed Llc Gamma-diketones as wnt/beta -catenin signaling pathway activators
WO2016029021A1 (en) 2014-08-20 2016-02-25 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN106279065A (zh) * 2015-05-12 2017-01-04 北京深蓝海生物医药科技有限公司 一种氢溴酸沃替西汀的精制转晶方法
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN109071374A (zh) * 2016-02-08 2018-12-21 Aaa化学公司 脂肪胺的芳基化
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN109912538B (zh) * 2019-01-22 2021-03-12 安徽赛乐普制药有限公司 一种抗抑郁药沃替西汀的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
IL161966A0 (en) * 2001-12-20 2005-11-20 Lundbeck & Co As H Aryloxyphenyl and arylsulfanylphenyl
EA015287B1 (ru) * 2006-06-16 2011-06-30 Х. Лундбекк А/С 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нти 5-нтдля лечения когнитивного нарушения
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
KR20150118146A (ko) 2015-10-21
HRP20170607T1 (hr) 2017-06-30
RU2652265C2 (ru) 2018-04-27
GEP201706749B (en) 2017-10-10
RS55932B1 (sr) 2017-09-29
CN104995181A (zh) 2015-10-21
PT2958903T (pt) 2017-05-26
WO2014128207A1 (en) 2014-08-28
MA38338A1 (fr) 2016-09-30
HK1216098A1 (en) 2016-10-14
DK2958903T3 (en) 2017-05-15
US9353073B2 (en) 2016-05-31
EA027756B1 (ru) 2017-08-31
RU2015134407A (ru) 2017-03-28
EP2958903A1 (en) 2015-12-30
TN2015000335A1 (en) 2017-01-03
AU2014220735B2 (en) 2017-06-22
CL2015002309A1 (es) 2016-03-04
SMT201700238T1 (it) 2017-07-18
PH12015501807B1 (en) 2019-05-31
US20160009670A1 (en) 2016-01-14
MA38338B1 (fr) 2018-10-31
CN104995181B (zh) 2017-03-08
MY172337A (en) 2019-11-21
MX2015010656A (es) 2015-12-17
AU2014220735A1 (en) 2015-08-20
BR112015019268A2 (pt) 2020-01-28
MX362355B (es) 2019-01-14
DOP2015000187A (es) 2015-11-30
SI2958903T1 (sl) 2017-09-29
IL240501A0 (en) 2015-09-24
CY1118883T1 (el) 2018-01-10
JP2016509042A (ja) 2016-03-24
SG11201506651SA (en) 2015-09-29
BR112015019268B1 (pt) 2023-01-10
PH12015501807A1 (en) 2015-11-09
KR102230628B1 (ko) 2021-03-22
PE20151589A1 (es) 2015-12-03
CA2901821A1 (en) 2014-08-28
LT2958903T (lt) 2017-08-25
EA201591349A1 (ru) 2015-12-30
IL240501B (en) 2018-08-30
CR20150423A (es) 2015-10-20
UA116236C2 (uk) 2018-02-26
EP2958903B1 (en) 2017-04-12
ME02671B (me) 2017-06-20
AP2015008640A0 (en) 2015-08-31
JP6464098B2 (ja) 2019-02-06
PL2958903T3 (pl) 2017-08-31
ES2625380T3 (es) 2017-07-19

Similar Documents

Publication Publication Date Title
GB2520596B (en) Manufacturing method
GB201321440D0 (en) Process
GB201312991D0 (en) Process
ZA201506050B (en) Vortioxetine manufacturing process
GB201307334D0 (en) Process
GB201416005D0 (en) Process
GB201421426D0 (en) Process
GB201322454D0 (en) Process
GB201318888D0 (en) Process
GB201421428D0 (en) Process
GB201401963D0 (en) Process
GB201401922D0 (en) Process
GB201322273D0 (en) Process
GB201320869D0 (en) Process
GB201314334D0 (en) Process
GB201307327D0 (en) Process
GB201302441D0 (en) Process
IL239449A0 (en) process
GB201316253D0 (en) Process
GB201307951D0 (en) Process
GB2520796B (en) Process
GB201323151D0 (en) Process
GB201418099D0 (en) Process
GB201303604D0 (en) Manufacturing process
GB201319357D0 (en) Process